Clinical utility gene card for: Tangier disease

Amanda J Hooper¹,2,3, Sally PA McCormick⁴, Robert A Hegele⁵ and John R Burnett*¹,2

1. DISEASE CHARACTERISTICS

1.1 Name of the disease (synonyms)
Tangier disease (familial high-density lipoprotein deficiency; analphalipoproteinemia).

1.2 OMIM# of the disease
205400.

1.3 Name of the analysed genes or DNA/chromosome segments
ABCA1.

1.4 OMIM# of the gene(s)
600046.

1.5 Mutational spectrum
The recessive disorder Tangier disease is caused by variants in the ABCA1 gene, which encodes the ATP-binding cassette transporter 1. This transporter facilitates the efflux of cholesterol from cells to nascent high-density lipoprotein (HDL) particles. The ABCA1 gene consists of 50 exons (49 are coding) spanning 149 kilobases. Loss-of-function variants result in reduced ABCA1 synthesis or activity and demonstrate a reduced cholesterol efflux capacity; loss-of-function missense variants may disrupt binding with apolipoprotein (apo) A-I and trafficking of the ABCA1 protein to the plasma membrane.

1.6 Analytical methods
Sequencing (Sanger or NGS). The gene includes 49 coding exons and massively parallel sequencing methods may therefore be more cost-effective than Sanger sequencing.

1.7 Analytical validation
Variant(s) should be confirmed by Sanger sequencing of the relevant region of ABCA1. Correlation of variant status with HDL cholesterol levels within a family may be useful.

1.8 Estimated frequency of the disease (incidence at birth ('birth prevalence') or population prevalence)
If known to be variable between ethnic groups, please report:
With the exception of small founder populations (eg, Tangier Island, Virginia, after which the disorder is named), Tangier disease is very rare. On the basis of allele frequencies of loss-of-function variants (frameshift, nonsense and splicing only; not missense) in the ExAC database, 1 in 400 individuals is heterozygous for a loss-of-function variant, giving Tangier disease a global prevalence of at least 1 in 640 000 (Exome Aggregation Consortium; http://exac.broadinstitute.org/).

1.9 Diagnostic Setting

A. (Differential) diagnostics
B. Predictive testing
C. Risk assessment in relatives
D. Prenatal

Comment: Use of genetic testing is essentially limited to confirmatory diagnosis in a subject suspected to be affected, rather than other applications such as predictive testing or prenatal diagnosis.

2. TEST CHARACTERISTICS

| Genotype or disease | Present | Absent |
|---------------------|---------|--------|
| A: True positives   |         |        |
| B: False positives  |         |        |
| D: True negative    |         |        |
| C: False negative   |         |        |

2.1 Analytical sensitivity
(proportion of positive tests if the genotype is present)
Approximately 100%.

2.2 Analytical specificity
(proportion of negative tests if the genotype is not present)
Approximately 100%.

2.3 Clinical sensitivity
(proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases a general statement should be given, even if a quantification can only be made case by case.
Tangier disease is characterised by severe deficiency or absence of HDL in the circulation resulting in tissue accumulation of cholesteryl esters throughout the body, particularly in the reticuloendothelial system. The major clinical signs of Tangier disease include hyperplastic yellow-orange tonsils, hepatosplenomegaly and peripheral neuropathy, which may be relapsing in nature. The clinical expression of Tangier disease, however, is variable. Some patients can present with haematological abnormalities including thrombocytopenia, reticulocytosis, stomatocytes and haemolytic anaemia. Ocular abnormalities include corneal opacities, which are mild and do not impair vision. Tangier disease patients have a moderately increased risk for coronary artery disease, with early coronary heart disease observed in some families, although this is an inconsistent association.7-10

3.1 (Differential) diagnostics: The tested person is clinically affected

3. CLINICAL UTILITY
3.1 (Differential) diagnostics: The tested person is clinically affected
(To be answered if in 1.9 'A' was marked)

3.1.1 Can a diagnosis be made other than through a genetic test?

No

Yes

☐ (continue with 3.1.4)

☐ Clinically

☐ Imaging

☐ Endoscopy

☐ Biochemistry

☐ Electrophysiology

☐ Other (please describe)

3.1.2 Describe the burden of alternative diagnostic methods to the patient

Tangier disease is characterised by hypocholesterolaemia, extremely low or absent levels of HDL cholesterol (as well as apo A-I and apo A-II), modestly decreased LDL cholesterol and elevated triglycerides in plasma. Two-dimensional gel electrophoresis shows the presence of the pre-β-HDL subfraction, but the absence of α-migrating HDL. Also, cellular cholesterol efflux from fibroblasts is markedly reduced.

Obligate heterozygotes have plasma HDL cholesterol concentrations that are approximately one-half of normal, but are asymptomatic and have no clinical manifestations. Two-dimensional gel electrophoresis shows presence of the pre-β-HDL subfraction, with detectable, but reduced α-migrating HDL along with half-normal fibroblast cholesterol efflux capacity.

3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?

Not applicable.

3.1.4 Will disease management be influenced by the result of a genetic test?

No ☐

Yes ☑

☐ Therapy (please describe)

There is no specific treatment for Tangier disease. Tonsillectomy may be required in case of significant tonsillar enlargement.

☐ Prognosis (please describe)

Prognosis in Tangier disease is usually good and depends mainly on the progression of peripheral neuropathy. Tangier disease patients have a moderate increased risk of coronary artery disease.

☐ Management (please describe)

The clinical follow-up and management of Tangier disease patients should include cardiovascular risk assessment including noninvasive assessment of atherosclerotic plaque burden, together with neurological and ophthalmological examination on an annual basis.

3.2 Predictive Setting: The tested person is clinically unaffected but carries an increased risk based on family history
(To be answered if in 1.9 'B' was marked)

3.2.1 Will the result of a genetic test influence lifestyle and prevention?

If the test result is positive (please describe) Not applicable.

If the test result is negative (please describe) Not applicable.

3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no genetic test has been done (please describe)?

Not applicable.

3.3 Genetic risk assessment in family members of a diseased person
(To be answered if in 1.9 'C' was marked)

3.3.1 Does the result of a genetic test resolve the genetic situation in that family?

Not applicable.

3.3.2 Can a genetic test in the index patient save genetic or other tests in family members?

Not applicable.
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in a family member?
Not applicable.

3.4 Prenatal diagnosis
(To be answered if in 1.9 'D' was marked)

3.4.1 Does a positive genetic test result in the index patient enable a prenatal diagnostic?
Not applicable.

4. IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe). Yes; a positive test result for either homozygous or heterozygous status should prompt ongoing monitoring of modifiable cardiovascular risk factors.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by EuroGentest2 (Unit 2: 'Genetic testing as part of health care'), a Coordination Action under FP7 (Grant Agreement Number 261469) and the European Society of Human Genetics.